Launched in 2018, AfriKADIA is a consortium of ten organizations working to find improved treatments and diagnostic tools for visceral leishmaniasis in eastern Africa.
The AfriKADIA consortium’s main mandate is to conduct a large-scale Phase III clinical trial to assess the efficacy and safety of a combination of oral miltefosine (MF) and paromomycin (PM) in treating visceral leishmaniasis. If found to be efficacious, the introduction of miltefosine in combination with paromomycin will reduce both the difficulty in administering treatment and the length of hospital stays for patients.
Although effective, the current treatment used to treat visceral leishmaniasis in eastern Africa remains sub-optimal as patients can suffer from rare but major side effects, such as cardiotoxicity, hepatotoxicity, and pancreatitis. The treatment is also difficult to administer, since patients must be hospitalized and endure two painful injections every day for 17 days.
The clinical trial is running hand-in-hand with an assessment of innovative, non-invasive diagnostic tools for detection and management of visceral leishmaniasis cases in routine patient care.
The consortium is comprised of: three universities and one research institution from eastern Africa with many years of experience in tropical disease research; four European research institutions with a track record in field-based research; and two not-for-profit product development partnerships specialising in R&D for neglected diseases.
News & resources
- 3 October 2022 - DNDi 2022 Projects of the Year recognize partners and colleagues for their work in developing new treatments for leishmaniasis
- 30 September 2022 - New, combined treatment for VL patients becomes effective in East Africa, Ethiopian Herald
- 30 September 2022 - Hope for kala-azar patients as new treatment is discovered, Nation
- 29 September 2022 - New treatment for visceral leishamaniasis effective – study says, Science Africa
- 29 September 2022 - Better, shorter combination treatment for people with visceral leishmaniasis shown to be effective in Eastern Africa
- 29 September 2022 - The Science Explained: Evaluating an alternative treatment regimen for visceral leishmaniasis in Eastern Africa
- 27 September 2022 - Paromomycin and miltefosine combination as an alternative to treat patients with visceral leishmaniasis in Eastern Africa: A randomized, controlled, multicountry trial, Clinical Infectious Diseases
- 20 June 2022 - My battle and triumph over trickster disease – Kala azar, People Daily
- 10 September 2019 - Sand fly bringing life-threatening kalaazar to semi-arid counties, The East African
- 13 April 2018 - Clinical trial to find new treatment for visceral leishmaniasis begins in eastern Africa
- KalaCORE: partnership to support the control and elimination of visceral leishmaniasis in six countries (India, Nepal, Bangladesh, Ethiopia, Sudan, South Sudan)
- WHO’s fact sheet on leishmaniasis
- Neglected tropical diseases course now accessible via eLearning by WHO
This project (grant RIA2016S-1635) is part of the European and Developing Countries Clinical Trials Partnership Association (EDCTP2) programme supported by the European Union.
Other private foundations and individuals
Get our latest news, personal stories, research articles, and job opportunities.